Theriva’s oncolytic virus succeeds in pancreatic cancer study, but stock fallsnews2025-05-07T14:18:41+00:00May 7th, 2025|Endpoints News|
CRISPR Therapeutics’ gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%news2025-05-07T11:00:16+00:00May 7th, 2025|Endpoints News|
Vinay Prasad’s FDA appointment sends biotech stocks lowernews2025-05-07T10:45:08+00:00May 7th, 2025|Endpoints News|
Marea heads to Phase 2b after updated biomarker data show CV drug’s promisenews2025-05-07T10:00:34+00:00May 7th, 2025|Endpoints News|
Vertex pauses study of mRNA therapy for cystic fibrosisnews2025-05-06T14:58:35+00:00May 6th, 2025|Endpoints News|
Aldeyra plots third FDA filing for dry eye disease drug after latest Phase 3 datanews2025-05-06T10:57:00+00:00May 6th, 2025|Endpoints News|
PTC’s Huntington’s study succeeds, but accelerated approval uncertainnews2025-05-05T19:59:13+00:00May 5th, 2025|Endpoints News|
BioNTech doesn’t see ‘near-term’ impact from RFK Jr.’s vaccine policy proposalnews2025-05-05T17:25:45+00:00May 5th, 2025|Endpoints News|
AI biotech Recursion cuts pipeline to ‘sharpen focus’news2025-05-05T15:17:46+00:00May 5th, 2025|Endpoints News|
J&J eye disease gene therapy bota-vec fails Phase 3news2025-05-05T13:29:50+00:00May 5th, 2025|Endpoints News|
